Method of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38

Inventors

O'DWYER, Michael Eamon Peter

Assignees

National University of Ireland Galway NUI • Onk Therapeutics Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10799536-B2

Patent

Publication Date

2020-10-13

Expiration Date


Abstract

Disclosed herein are engineered natural killer cells that have been modified to express chimeric antigen receptors (CARs). The cells optionally contain other modifications that improve tumor specific cytotoxicity and homing to tumor sites. Also contemplated are methods for using the engineered natural killer cells to treat patients with cancer.

Core Innovation

The invention describes engineered NK-cell pharmaceutical compositions and treatment methods for cancers and blood cancers by employing chimeric antigen receptors (CARs) that target cancer-associated antigens including CD38 and at least one additional antigen selected from a list of named antigens. The CAR targeting domain is defined by sequence identity to specified SEQ ID NOs and by an affinity constraint for CD38 described as lower affinity for CD38 than Daratumumab.

The engineered NK cells include CAR designs with a human CD8α transmembrane domain and intracellular signaling components DAP10, DAP12, 2B4 (CD244), and/or 4-1BB (CD137), together with human CD3ζ. The CAR targeting domain constraints specify permitted sequence identity ranges and exact-match options to SEQ ID NOs, including specified pairs, which characterize the CD38 CAR targeting elements.

The compositions can additionally include a second chimeric antigen receptor and a mutant TRAIL polypeptide with DR4 (TNFRSF10A) and/or DR5 (TNFRSF10B) targets. The NK cells may also be engineered by genomic integration and by deletion and/or siRNA knockdown of inhibitory checkpoint receptors, including multiple named checkpoint inhibitory receptors, to alter inhibitory signaling in NK cells.

The document also describes engineered NK-cell behavior and in vivo relevance by comparing an E-selectin ligand expression phenotype, including HECA-452 reactivity, and reporting effects on in vitro migration/rolling and in vivo homing, with anti-multiple myeloma efficacy testing of affinity-varied CD38 CAR NK cells. It further describes TRAIL variant knock-in/overexpression and checkpoint inhibitory receptor knockdown/knockout approaches in the disclosed testing context.

Claims Coverage

The partial content identifies two independent claims directed to treating multiple myeloma using CD38 CAR-modified natural killer (NK) cells that kill CD38-expressing MM cells. The claim set includes multiple inventive features that differ primarily in the specified CD38 CAR variable region sequence options.

Treating multiple myeloma using CD38 CAR-modified NK cells

A method of treating multiple myeloma (MM) in a mammal by administering a natural killer (NK) cell modified to express a chimeric antigen receptor (CAR) for CD38, wherein the administering kills MM cells expressing CD38.

CD38 CAR defined by heavy and light variable region sequence options

The CD38 CAR comprises a heavy chain variable region comprising SEQ ID NO: 1 or SEQ ID NO: 7 and a light chain variable region comprising SEQ ID NO: 23 or SEQ ID NO: 28.

Treating multiple myeloma using a CD38 CAR with specific variable region sequences

A method of treating multiple myeloma (MM) in a mammal by administering a natural killer (NK) cell modified to express a chimeric antigen receptor (CAR) for CD38, wherein the administration kills MM cells expressing CD38 and wherein the CD38 CAR comprises a heavy chain variable region comprising SEQ ID NO: 1 and a light chain variable region comprising SEQ ID NO: 23.

Overall, the independent claims cover CD38-targeted CAR-modified NK cell treatment of multiple myeloma with killing of CD38-expressing MM cells, and they define the CD38 CAR by specified heavy-chain and light-chain variable region sequence identifiers (with one independent claim allowing SEQ ID NO: 1 or SEQ ID NO: 7 and SEQ ID NO: 23 or SEQ ID NO: 28, and the other fixing SEQ ID NO: 1 with SEQ ID NO: 23).

Stated Advantages

Improved cytotoxicity and target-cell apoptosis as reported in the disclosed testing context.

Anti-multiple myeloma efficacy as reported for affinity-varied CD38 CAR NK cells.

Altered inhibitory signaling in NK cells by deletion and/or siRNA knockdown of inhibitory checkpoint receptors.

Engagement of TRAIL death receptor pathways through mutant TRAIL polypeptides with DR4/DR5 targets.

Documented Applications

Treatment of multiple myeloma, including anti-multiple myeloma efficacy testing of affinity-varied CD38 CAR NK cells.

Treatment of leukemia/lymphoma/myeloma using the disclosed engineered NK-cell pharmaceutical compositions, including multiple myeloma.

Assessment of engineered NK-cell homing, including in vitro migration/rolling and in vivo homing related to E-selectin ligand expression phenotype (HECA-452 reactivity).

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.